Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Is Cancer A Disease of the Modern World? | Main | Laser Nematode Surgery! »

October 21, 2010

Apotex's Plavix Adventure: Four Years Later

Email This Entry

Posted by Derek

Remember the Plavix Confusion of 2006? That's when Canadian generic company Apotex managed to jump onto the market for a few weeks with its own version of the BMS/Sanofi-Aventis blockbuster. It was always a bit unclear whether they had the right to do that - there was a case that the company had played rough but fair with some tricky language in their agreements with the two pharmas. Still, Apotex racked up over 800 million dollars in sales while everyone was sorting that out.

Well, four years down the road, a judge has ruled that Apotex owes BMS and S-A damages for their adventure: half the sales, plus interest. That's still less than the triple damages that could be obtained in an open-and-shut case of patent infringement, but it's pretty substantial. I wonder how much of the money Apotex still has handy?

Comments (9) + TrackBacks (0) | Category: Cardiovascular Disease | Patents and IP


COMMENTS

1. John Doe on October 21, 2010 8:57 AM writes...

Don't Worry, we are fine.

Permalink to Comment

2. darwin on October 21, 2010 9:32 AM writes...

always easier to apologize that to ask for permission.

Permalink to Comment

3. BFS on October 21, 2010 9:54 AM writes...

While Apotex was deemed liable for $442M in damages, plus $108M in prejudgment interest, the company still made about $300M from their foray. Not bad, considering the drug was only on the market for three weeks before the PI issued.

Permalink to Comment

4. Rock on October 21, 2010 10:42 AM writes...

How do they come up with that interest amount?
My bank is only paying me 0.5%, I would love to get that ROI, particularly over the past few years....

Permalink to Comment

5. ayj on October 21, 2010 10:45 AM writes...

You really think the products were 0-cost? Any company prepare so much cash for fine? It's time to sell or close.

Permalink to Comment

6. Brian on October 21, 2010 1:27 PM writes...

I am not sure how much money Apotex does have, but I can tell you that when I started my career working for them as an Analytical R & D chemist, I certainly worked on several drugs. It was a great way to get initiated into the field of pharmaceuticals because there was a method for everything. Having worked for both a brand-name and a generic company, I can get a feel for both sides of a product, the cost of R & D for the development of the new product and marketing versus the fight to provide a lower-cost generic version.

Permalink to Comment

7. Tokamak on October 21, 2010 9:34 PM writes...

Good thing they didn't steal the IP for personal, non-commercial use. Otherwise they'd be on the hook for $576,000,000,000; if recent copyright cases are any indication.

Permalink to Comment

8. Peej on October 27, 2010 7:03 PM writes...

The reason why it wasnt triple damages was that the BMS CEO, Peter Dolan, signed that provision away in a deal with Apotex in negotiations. Brilliant, huh?

Permalink to Comment

9. Terry on June 12, 2011 2:15 PM writes...

indeed, in china there is a company named salubris got the exclusivity in china for this drug, the annul sale now is around 100 million dollars, sometimes it is easier to start a generic drug in china, and the medical market of china is the second one after US's, which will exceed US market in 2030.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought